Induction of Heme Oxygenase-1 by Na+-H+ exchanger 1 protein plays a crucial role in Imatinib-resistant chronic myeloid leukemia cells

Journal of Biological Chemistry

Volumn 290, Issue 20, 2015, Pages 12558-12571

  Ma, Dan ^a   Fang, Qin ^a   Wang, Ping ^a,b   Gao, Rui ^a,b   Wu, Weibing ^a,b   Lu, Tangsheng ^a   Cao, Lu ^a   Hu, Xiuying ^a,b   Wang, Jishi ^a,b  

^a GUIZHOU MEDICAL UNIVERSITY   (China)

^b Key Laboratory of Hematological Disease Diagnostic and Treat Centre of Guizhou Province   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CELL CULTURE; CELL DEATH; DISEASES; ENZYME INHIBITION; PORPHYRINS;

AFTER-TREATMENT; CHEMORESISTANCE; CHRONIC MYELOID LEUKEMIAS; DOWN-REGULATION; HEME OXYGENASE-1; INTRACELLULAR PH; POLY(ADP RIBOSE) POLYMERASE 1; TYROSINE KINASE INHIBITOR;

PATIENT TREATMENT;

CASPASE 3; HEME OXYGENASE 1; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN KINASE C BETA; SODIUM PROTON EXCHANGE PROTEIN 1; TRANSCRIPTION FACTOR NRF2; BENZAMIDE DERIVATIVE; CATION TRANSPORT PROTEIN; HMOX1 PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PRKCB PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; SLC9A1 PROTEIN, HUMAN; SODIUM PROTON EXCHANGE PROTEIN; TUMOR PROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MIDDLE AGED; MYELOID LEUKEMIA CELL LINE; OXIDATIVE STRESS; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; VERY ELDERLY; YOUNG ADULT; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CLINICAL TRIAL; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; K562 CELL LINE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; PATHOLOGY;

ADULT; AGED; APOPTOSIS; BENZAMIDES; CATION TRANSPORT PROTEINS; DRUG RESISTANCE, NEOPLASM; ENZYME INDUCTION; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HEME OXYGENASE-1; HUMANS; IMATINIB MESYLATE; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; NEOPLASM PROTEINS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PIPERAZINES; PROTEIN KINASE C BETA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SODIUM-HYDROGEN ANTIPORTER;

EID: 84929333860     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.626960     Document Type: Article

References (44)

1. Trela, E., Glowacki, S., and Blasiak, J. (2014) Therapy of chronic myeloid leukemia: twilight of the imatinib era? ISRN Oncol. 2014, 596483
2. de Almeida, M. H., Fogliatto, L., and Couto, D. (2014) Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia. Rev. Bras. Hematol. Hemoter. 36, 54-59
3. Breccia, M., and Alimena, G. (2014) Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatmentfree remission as a new goal in chronic myeloid leukemia. Cancer Lett. 347, 22-28
4. Sacha, T. (2014) Imatinib in chronic myeloid leukemia: an overview. Mediterr. J. Hematol. Infect. Dis. 6, e2014007
5. Baccarani, M., Castagnetti, F., Gugliotta, G., Palandri, F., and Rosti, G. (2014) Treatment recommendations for chronic myeloid leukemia. Mediterr. J. Hematol. Infect. Dis. 6, e2014005
6. Marin, D. (2014) Patient with chronic myeloid leukemia in complete cytogenetic response: what does it mean, and what does one do next? J. Clin. Oncol. 32, 379-384
7. Savona, M. R., and Saglio, G. (2013) Identifying the time to change BCRABL inhibitor therapy in patients with chronic myeloid leukemia. Acta Haematol. 130, 268-278
8. Jabbour, E. J., Cortes, J. E., and Kantarjian, H. M. (2013) Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin. Lymphoma Myeloma Leuk. 13, 515-529
9. Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., Herrmann, R., Lynch, K. P., and Hughes, T. P. (2002) High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99, 3472-3475
10. Xu, H. L., Wang, Z. J., Liang, X. M., Li, X., Shi, Z., Zhou, N., and Bao, J. K. (2014) In silico identification of novel kinase inhibitors targeting wild-type and T315I mutant ABL1 from FDA-approved drugs. Mol. Biosyst. 10, 1524-1537
11. Kantarjian, H., O'Brien, S., Jabbour, E., Garcia-Manero, G., Quintas-Cardama, A., Shan, J., Rios, M. B., Ravandi, F., Faderl, S., Kadia, T., Borthakur, G., Huang, X., Champlin, R., Talpaz, M., and Cortes, J. (2012) Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 119, 1981-1987
12. Kim, D., Goh, H. G., Kim, S. H., Choi, S. Y., Park, S. H., Jang, E. J., and Kim, D. W. (2012) Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation. Int. J. Hematol. 96, 47-57
13. Kawajiri, C., Tanaka, H., Hashimoto, S., Takeda, Y., Sakai, S., Takagi, T., Takeuchi, M., Ohwada, C., Sakaida, E., Shimizu, N., and Nakaseko, C. (2014) Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status. Int. J. Hematol. 99, 513-518
14. Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., Kung, A. L., Mestan, J., Daley, G. Q., Callahan, L., Catley, L., Cavazza, C., Azam, M., Neuberg, D., Wright, R. D., Gilliland, D. G., and Griffin, J. D. (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7, 129-141
15. Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., and Sawyers, C. L. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399-401
16. Yun, S. M., Jung, K. H., Kim, S. J., Fang, Z., Son, M. K., Yan, H. H., Lee, H., Kim, J., Shin, S., Hong, S., and Hong, S. S. (2014) HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. Cancer Lett. 348, 50-60
17. Elias, M. H., Baba, A. A., Azlan, H., Rosline, H., Sim, G. A., Padmini, M., Fadilah, S. A., and Ankathil, R. (2014) BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome. Leuk. Res. 38, 454-459
18. Mayerhofer, M., Gleixner, K. V., Mayerhofer, J., Hoermann, G., Jaeger, E., Aichberger, K. J., Ott, R. G., Greish, K., Nakamura, H., Derdak, S., Samorapoompichit, P., Pickl, W. F., Sexl, V., Esterbauer, H., Schwarzinger, I., Sillaber, C., Maeda, H., and Valent, P. (2008) Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. Blood 111, 2200-2210
19. Ozkan, P., and Mutharasan, R. (2002) A rapid method for measuring intracellular pH using BCECF-AM. Biochim. Biophys. Acta 1572, 143-148
20. Snabaitis, A. K., Cuello, F., and Avkiran, M. (2008) Protein kinase B/Akt phosphorylates and inhibits the cardiac Na+/H+exchanger NHE1. Circ. Res. 103, 881-890
21. Ruvolo, P. P., Zhou, L., Watt, J. C., Ruvolo, V. R., Burks, J. K., Jiffar, T., Kornblau, S., Konopleva, M., and Andreeff, M. (2011) Targeting PKCmediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia-derived cell lines and blast cells. J. Cell. Biochem. 112, 1696-1707
22. Lutzny, G., Kocher, T., Schmidt-Supprian, M., Rudelius, M., Klein-Hitpass, L., Finch, A. J., Dürig, J., Wagner, M., Haferlach, C., Kohlmann, A., Schnittger, S., Seifert, M., Wanninger, S., Zaborsky, N., Oostendorp, R., Ruland, J., Leitges, M., Kuhnt, T., Schäfer, Y., Lampl, B., Peschel, C., Egle, A., and Ringshausen, I. (2013) Protein kinase c-β-dependent activation of NF-κB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo. Cancer Cell 23, 77-92
23. Saba, N. S., and Levy, L. S. (2012) Protein kinase C-β inhibition induces apoptosis and inhibits cell cycle progression in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma cells. J. Investig. Med. 60, 29-38
24. Kobayashi, M., and Yamamoto, M. (2005) Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation. Antioxid. Redox. Signal. 7, 385-394
25. Wang, G., Hamid, T., Keith, R. J., Zhou, G., Partridge, C. R., Xiang, X., Kingery, J. R., Lewis, R. K., Li, Q., Rokosh, D. G., Ford, R., Spinale, F. G., Riggs, D. W., Srivastava, S., Bhatnagar, A., Bolli, R., and Prabhu, S. D. (2010) Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. Circulation 121, 1912-1925
26. Akagi, R., Takahashi, T., and Sassa, S. (2005) Cytoprotective effects of heme oxygenase in acute renal failure. Contrib. Nephrol. 148, 70-85
27. Miyake, M., Fujimoto, K., Anai, S., Ohnishi, S., Kuwada, M., Nakai, Y., Inoue, T., Matsumura, Y., Tomioka, A., Ikeda, T., Tanaka, N., and Hirao, Y. (2011) Heme oxygenase-1 promotes angiogenesis in urothelial carcinoma of the urinary bladder. Oncol. Rep. 25, 653-660
28. Sass, G., Leukel, P., Schmitz, V., Raskopf, E., Ocker, M., Neureiter, D., Meissnitzer, M., Tasika, E., Tannapfel, A., and Tiegs, G. (2008) Inhibition of heme oxygenase 1 expression by small interfering RNA decreases orthotopic tumor growth in livers of mice. Int. J. Cancer. 123, 1269-1277
29. Du, Y., Bales, K. R., Dodel, R. C., Hamilton-Byrd, E., Horn, J. W., Czilli, D. L., Simmons, L. K., Ni, B., and Paul, S. M. (1997) Activation of a caspase 3-related cysteine protease is required for glutamate-mediated apoptosis of cultured cerebellar granule neurons. Proc. Natl. Acad. Sci. U.S.A. 94, 11657-11662
30. Lin, T. K., Chen, S. D., Chuang, Y. C., Lin, H. Y., Huang, C. R., Chuang, J. H., Wang, P. W., Huang, S. T., Tiao, M. M., Chen, J. B., and Liou, C. W. (2014) Resveratrol partially prevents rotenone-induced neurotoxicity in dopaminergic SH-SY5Y cells through induction of heme oxygenase-1 dependent autophagy. Int. J. Mol. Sci. 15, 1625-1646
31. Xenaki, D., Pierce, A., Underhill-Day, N., Whetton, A. D., and Owen-Lynch, P. J. (2004) Bcr-Abl-mediated molecular mechanism for apoptotic suppression in multipotent haemopoietic cells: a role for PKCβII. Cell. Signal. 16, 145-156
32. Wegiel, B., Gallo, D., Csizmadia, E., Harris, C., Belcher, J., Vercellotti, G. M., Penacho, N., Seth, P., Sukhatme, V., Ahmed, A., Pandolfi, P. P., Helczynski, L., Bjartell, A., Persson, J. L., and Otterbein, L. E. (2013) Carbon monoxide expedites metabolic exhaustion to inhibit tumor growth. Cancer Res. 73, 7009-7021
33. Ursu, O. N., Sauter, M., Ettischer, N., Kandolf, R., and Klingel, K. (2014) Heme oxygenase-1 mediates oxidative stress and apoptosis in coxsackievirus b3-induced myocarditis. Cell Physiol. Biochem. 33, 52-66
34. Tibullo, D., Barbagallo, I., Giallongo, C., La Cava, P., Parrinello, N., Vanella, L., Stagno, F., Palumbo, G. A., Li Volti, G., and Di Raimondo, F. (2013) Nuclear translocation of heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells. Curr. Pharm. Des. 19, 2765-2770
35. Lee, B. K., Yoon, J. S., Lee, M. G., and Jung, Y. S. (2014) Protein kinase C-β mediates neuronal activation of Na+/H+ exchanger-1 during glutamate excitotoxicity. Cell. Signal. 26, 697-704
36. Katayama, K., Yoshioka, S., Tsukahara, S., Mitsuhashi, J., and Sugimoto, Y. (2007) Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein. Mol. Cancer Ther. 6, 2092-2102
37. Voss, J., Posern, G., Hannemann, J. R., Wiedemann, L. M., Turhan, A. G., Poirel, H., Bernard, O. A., Adermann, K., Kardinal, C., and Feller, S. M. (2000) The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathways. Oncogene 19, 1684-1690
38. Liu, M., Li, D., Aneja, R., Joshi, H. C., Xie, S., Zhang, C., and Zhou, J. (2007) PO2-dependent differential regulation of multidrug resistance 1 gene expression by the c-Jun NH2-terminal kinase pathway. J. Biol. Chem. 282, 17581-17586
39. Zhou, J., Liu, M., Aneja, R., Chandra, R., Lage, H., and Joshi, H. C. (2006) Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase. Cancer Res. 66, 445-452
40. Oriente, F., Cabaro, S., Liotti, A., Longo, M., Parrillo, L., Pagano, T. B., Raciti, G. A., Penkov, D., Paciello, O., Miele, C., Formisano, P., Blasi, F., and Beguinot, F. (2013) PREP1 deficiency downregulates hepatic lipogenesis and attenuates steatohepatitis in mice. Diabetologia 56, 2713-2722
41. Bloom, D. A., and Jaiswal, A. K. (2003) Phosphorylation of Nrf2 at Ser40 by protein kinase C in response to antioxidants leads to the release of Nrf2 from INrf2, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional activation of antioxidant response elementmediated NAD(P)H:quinone oxidoreductase-1 gene expression. J. Biol. Chem. 278, 44675-44682
42. Hwang, Y. P., and Jeong, H. G. (2008) The coffee diterpene kahweol induces heme oxygenase-1 via the PI3K and p38/Nrf2 pathway to protect human dopaminergic neurons from 6-hydroxydopamine-derived oxidative stress. FEBS Lett. 582, 2655-2662
43. Randle, L. E., Goldring, C. E., Benson, C. A., Metcalfe, P. N., Kitteringham, N. R., Park, B. K., and Williams, D. P. (2008) Investigation of the effect of a panel of model hepatotoxins on the Nrf2-Keap1 defence response pathway in CD-1 mice. Toxicology 243, 249-260
44. Lau, A., Villeneuve, N. F., Sun, Z., Wong, P. K., and Zhang, D. D. (2008) Dual roles of Nrf2 in cancer. Pharmacol. Res. 58, 262-270